

1-way ANOVA LPS challenge

	serum	spleen	brain
IFN- γ	$F_{(2,15)} = 13.10$ p = 0.0002	$F_{(2,15)} = 30.27$ p <0.0001	$F_{(2,15)} = 5.056$ p = 0.0129
IL-1 β	$F_{(2,15)} = 48$ p <0.0001	$F_{(2,15)} = 56.45$ p <0.0001	$F_{(2,15)} = 40.97$ p <0.0001
IL-12	$F_{(2,15)} = 17.04$ p <0.0001	$F_{(2,15)} = 2.643$ n.s.	$F_{(2,15)} = 5.409$ p = 0.101

1-way ANOVA Salmonella infection

	serum	spleen	brain
IFN- γ	$F_{(3,20)} = 11.82$ p < 0.0001	$F_{(3,20)} = 16.95$ p <0.0001	$F_{(3,20)} = 5.820$ p = 0.0028
IL-1 β	$F_{(3,20)} = 1.533$ n.s.	$F_{(3,20)} = 7.443$ p = 0.0008	$F_{(3,20)} = 4.312$ p = 0.0112
IL-12	$F_{(3,20)} = 21.53$ p <0.0001	$F_{(3,20)} = 11.15$ p <0.0001	$F_{(3,20)} = 4.604$ p = 0.0085

repeated measures ANOVA for weight loss and burrowing behaviour

	body weight	burrowing
LPS	$F_{(1,16)} = 26.68$ p < 0.0001	$F_{(2,24)} = 288.6$ p <0.0001
Salmonella	$F_{(4,20)} = 11.96$ p <0.0001	$F_{(4,20)} = 11.64$ p <0.0001

2-way ANOVA IHC quantification

	Salmonella infection	LPS injection	Interaction
CD68	$F_{(1,10)} = 0.04$ p = 0.8443	$F_{(1,10)} = 7.09$ p = 0.0238	$F_{(1,10)} = 0.53$ p = 0.4826
CD11b	$F_{(1,10)} = 0.63$ p = 0.4441	$F_{(1,10)} = 2.96$ p = 0.1161	$F_{(1,10)} = 0.62$ p = 0.4509
ICAM-1	$F_{(1,14)} = 0.69$ p = 0.4212	$F_{(1,14)} = 11.78$ p = 0.0040	$F_{(1,14)} = 0.61$ p = 0.4478
VCAM-1	$F_{(1,14)} = 2.21$ p = 0.1596	$F_{(1,14)} = 9.24$ p = 0.0088	$F_{(1,14)} = 0.14$ p = 0.7106
MHCI	$F_{(1,14)} = 12.98$ p = 0.003	$F_{(1,14)} = 5.42$ p = 0.0354	$F_{(1,14)} = 1.11$ p = 0.3104
MHCII	$F_{(1,14)} = 24.81$ p = 0.0002	$F_{(1,14)} = 24.81$ p = 0.0002	$F_{(1,14)} = 10.0$ p = 0.0069
CD11c	$F_{(1,12)} = 11.68$ p = 0.0051	$F_{(1,12)} = 8.19$ p = 0.0143	$F_{(1,12)} = 5.59$ p = 0.0358

Abbreviations: ANOVA, analysis of variance; ICAM-1, intercellular adhesion molecule-1; IFN, interferon; IHC, immunohistochemistry; IL, interleukin; LPS, lipopolysaccharide; MCHI/I, major histocompatibility Class I/I; n.s., not significant; VCAM-1, vascular cell adhesion molecule-1.